By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • Target Enrollment in Child Spinal Muscular Atrophy Study Earns Ionis $2M Payment From Biogen – SMA News Today

Target Enrollment in Child Spinal Muscular Atrophy Study Earns Ionis $2M Payment From Biogen – SMA News Today

Sunday, 31 January, 2016

Target Enrollment in Child Spinal Muscular Atrophy Study Earns Ionis $2M Payment From Biogen – SMA News Today

Ionis Pharmaceuticals announced it has completed its target enrollment of the Phase 3 CHERISH study, a trial designed to support marketing approval of the drug candidate nusinersen in children with spinal muscular atrophy (SMA). The achievement earned ...

Read More

Source:Target Enrollment in Child Spinal Muscular Atrophy Study Earns Ionis $2M Payment From Biogen - SMA News Today

Categories :
  • Latest Headlines
  • Spinal muscular atrophy
  • Uncategorized
Socials :

Recent posts

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Our Awards and Partners

Copyright © 2022 All rights reserved